A Single-Site, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Glucodynamic Effects of LY3192767 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2018
At a glance
- Drugs LY 3192767 (Primary) ; Insulin glargine; Insulin peglispro
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 26 Jul 2018 Status changed to discontinued.
- 22 Jun 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 22 Jun 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.